Novartis AG has a commercial expansion opportunity in hand for its cholesterol-lowering injection Leqvio (inclisiran) with the US Food and Drug Administration approval of a broader label in patients with earlier stages of cardiovascular disease.
Novartis Gets Expansion For Earlier Use Of Leqvio
Leqvio was approved by the US FDA for a broad label for high cholesterol in patients with an increased risk of heart disease, expanding beyond the initial approval for patients with ASCVD.
More from Cardiovascular
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
The UK giant is forecasting peak sales of $5bn plus
More from Therapy Areas
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.